Medtronic receives u.s. fda approval for pipeline™ flex embolization device with shield technology™

First patient receives new shield surface modification, an advance in flow diversion therapy, at nyu langone health dublin, april 21, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced it has received approval from the united states food and drug administration (fda) for pipeline™ flex embolization device with shield technology™. medtronic developed shield technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy by introducing the first surface-modified implant device which demonstrates reduction in material thrombogenicity, a reduction in the tendency of the surface treatment material to create clots.
MDT Ratings Summary
MDT Quant Ranking